9 completed. 5 Phase 1, 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 3 | Completed 3 |
| Phase 3 | 3 | Completed 3 |
Follow Zosano Pharma Corporation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0 - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 48 | 2021-06-24 | 2021-09-17 |
| Double-Blind Comparison of the Efficacy and Safety of C213 to Placebo for the Acute Treatment of Cluster Headaches C213 Microneedle System, Placebo - Cluster Headache | Phase 2 / Phase 3 | Completed | Zosano Pharma Corporation | 42 | 2019-10-03 | 2022-06-14 |
| A Four-way Crossover Study of 3 Formulations of M207 With Intranasal Zolmitriptan in Healthy Volunteers M207 3.8 mg "Sled" (two 1.9 mg patches made on a "Sled" coater, foil pouches), M207 3.8 mg "MACAP" (two 1.9 mg patches made on a "MACAP" coater, foil cups), M207 3.8 mg "MiniMac" (two 1.9 mg patches made on a "MiniMac" coater, foil cups - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 24 | 2019-05-29 | 2021-11-18 |
| A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers A: M207 3.8mg, 30 min, upper arm, B: M207 3.8 mg, 30 min, thigh, C: M207 3.8 mg, 1 hr, upper arm - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 24 | 2018-11-01 | 2020-01-18 |
| A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine M207 Microneedle System - Migraine | Phase 3 | Completed | Zosano Pharma Corporation | 342 | 2017-11-07 | 2020-08-19 |
| Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine ZP-Zolmitriptan, Placebo - Acute Migraine | Phase 2 / Phase 3 | Completed | Zosano Pharma Corporation | 365 | 2016-06-01 | 2018-03-13 |
| A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen ZP-PTH, FORTEO - Postmenopausal Osteoporosis | Phase 1 | Completed | Zosano Pharma Corporation | 24 | 2015-06-01 | 2016-08-23 |
| Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia Glucagon (ZP-Glucagon), Glucagon (GlucaGen) - Hypoglycemia | Phase 1 | Completed | Zosano Pharma Corporation | 16 | 2015-01-01 | 2016-08-16 |
| Dose Ranging Study - Macroflux Parathyroid Hormone (PTH) in Postmenopausal Women With Osteoporosis teriparatide - Osteoporosis | Phase 2 | Completed | Zosano Pharma Corporation | 165 | 2007-06-01 | 2018-07-31 |
Migraine Disorders (5) · Cluster Headache (1) · Hypoglycemia (1) · Osteoporosis (1) · Osteoporosis, Postmenopausal (1)
Parathyroid Hormone (2) · Teriparatide (2) · zolmitriptan (2) · Glucagon (1) · Glucagon-Like Peptide 1 (1) · Nasal Sprays (1)
United States (7) · Australia (1)
Don Kellerman, PharmD (3) · Don Kellerman, Pharm.D. (2) · Donald Kellerman, Pharm.D. (1) · Hugh Coleman, DO (1) · Neale Cohen, MD (1) · Thorsten von Stein, MD, Ph.D (1)